“…PDE5, whose presence in cardiomyocytes continues to be a matter of debate, is largely cytosolic and apparently more involved in breakdown of cytosolic cGMP pools generated by NO-GC activation (Palmer and Maurice, 2000;Corbin et al, 2005;Castro et al, 2006;Fischmeister et al, 2006;Lukowski et al, 2010). The catalytic activities of the PDE3 family have long been recognized as having important impact on lipolysis, glycogenolysis, insulin secretion, and cardiac function (Degerman et al, 1997;Thompson et al, 2007). PDE3 was the target of the first pharmacological agent (milrinone) approved for blocking PDE action (Seino et al, 1995).…”